Related Experiment Video
Updated: Nov 1, 2025
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.1K
Alzheimer's Disease Genetics: A Dampened Microglial Response?
Zena K Chatila1, Elizabeth M Bradshaw1
1Columbia University Medical Center, New York, NY, USA.
Summary
Alzheimer's disease (AD) involves microglia, the brain's immune cells. Genetic factors dampen microglial function in AD, suggesting therapeutic targets for this neurodegenerative condition.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Alzheimer's disease (AD) is a major age-related neurodegenerative disorder.
- Microglia, the central nervous system's immune cells, are critically implicated in AD pathogenesis by genetic studies.
- Understanding microglial dysfunction in AD is crucial for developing effective treatments.
Purpose of the Study:
- To review genetic studies implicating microglia in Alzheimer's disease.
- To clarify the biological mechanisms underlying microglial involvement in AD.
- To identify potential therapeutic targets based on converging microglial pathways.
Main Methods:
- Review of unbiased genetic studies in Alzheimer's disease.
- Analysis of microglial pathways and their dysfunction in AD.
- Examination of protein interactions and shared regulatory mechanisms.
Main Results:
- Genetic risk factors converge to impair activating microglial receptors and enhance inhibitory receptors.
- This leads to a dampened microglial phenotype in Alzheimer's disease.
- Associated microglial proteins interact and share pathways, indicating points of convergence.
Conclusions:
- Microglia play a central role in Alzheimer's disease pathogenesis.
- Dysfunctional microglial pathways represent strategic targets for therapeutic intervention.
- Further research into these converging pathways is warranted for AD treatment development.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
934
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
934
01:28Human Genetics
936
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
936
01:22Alzheimer's Disease: Treatment
448
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
448